(Q37976114)

26 August 2017

title

Mesenchymal stromal cells for tissue-engineered tissue and organ replacements (English)

1 reference

26 August 2017

4

Paolo Macchiarini

1 reference

26 August 2017

Silvia Baiguera

1

1 reference

26 August 2017

Philipp Jungebluth

series ordinal

2

1 reference

26 August 2017

Benedetta Mazzanti

series ordinal

3

1 reference

26 August 2017

language of work or name

1 reference

16 January 2012

1 reference

26 August 2017

published in

Transplant International

1 reference

26 August 2017

volume

25

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

369-382

1 reference

Tissue-engineered autologous bladders for patients needing cystoplasty

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Bioengineered skin substitutes for the management of burns: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Clinical transplantation of a tissue-engineered airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Experimental generation of a tissue-engineered functional and vascularized trachea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human tracheal chondrocytes as a cell source for augmenting stenotic tracheal segments: the first feasibility study in an in vivo culture system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Generation and transplantation of an autologous vascularized bioartificial human tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Hunt for pluripotent stem cell -- regenerative medicine search for almighty cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

The possible use of stem cells in regenerative medicine: dream or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human amniotic membrane as an alternative source of stem cells for regenerative medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Isolation of amniotic stem cell lines with potential for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Stem cells derived from amniotic fluid: new potentials in regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Immunogenicity of induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

In vitro cardiomyogenic potential of human umbilical vein-derived mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

In vitro differentiation of size-sieved stem cells into electrically active neural cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

A perivascular origin for mesenchymal stem cells in multiple human organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Why are MSCs therapeutic? New data: new insight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Immunoregulatory function of mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Immune modulation by mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human mesenchymal stem cells modulate allogeneic immune cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Interactions between human mesenchymal stem cells and natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Toll-like receptors and their ligands control mesenchymal stem cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

The role of indoleamine 2,3-dioxygenase in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells avoid allogeneic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human mesenchymal stem cells promote survival of T cells in a quiescent state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Adult stem cells in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Adult stem cell transplantation in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human mesenchymal stem cells modulate B-cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cell therapy: Two steps forward, one step back

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Inflammatory Cytokine Induced Regulation of Superoxide Dismutase 3 Expression by Human Mesenchymal Stem Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Tissue engineering and cell based therapies, from the bench to the clinic: the potential to replace, repair and regenerate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Regenerative medicine: basic concepts, current status, and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Transdifferentiation: why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Adult stem cell plasticity: will engineered tissues be rejected?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

The key role of adult stem cells: therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Stem cells in regenerative medicine: introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Promising new sources for pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Umbilical cord transplantation: epilogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Umbilical cord stem cell: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Epigenetic memory in induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Human induced pluripotent stem cells: the past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Harnessing the potential of induced pluripotent stem cells for regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Immunomodulation by mesenchymal stem cells and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

RETRACTED: Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2011.01426.X

10.1111/J.1432-2277.2011.01426.X

21 January 2018

Identifiers

DOI

1 reference

release_jfib3ylcrrc7ngzurmwprqcknm

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jfib3ylcrrc7ngzurmwprqcknm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference